Sai Parenteral's IPO Details
The Sai Parenteral's IPO is a book build issue with a total issue size of ₹409 cr, comprising of fresh issue of 7270408 equity shares., and a offer for sale of 3157880 equity shares. Sai Parenteral's IPO opened for subscription on Mar 24, 2026 and closed on Mar 27, 2026. Sai Parenteral's IPO is set price band at ₹372 to ₹392 per share, with a lot size of 38 shares. Minimum investment for Retail investors was ₹14,896.00 (at the upper price band) to apply for one lot.
The basis of allotment got finalized on Mar 30, 2026, and listed on both the NSE and BSE on Apr 02, 2026.
Bigshare Services Pvt Ltd has been appointed as the registrar. Arihant Capital Markets Ltd are the Book Running Lead Manager for the issue.
Before investing in the Sai Parenteral's IPO, investors should review the company's financial performance, business objectives, and risk factors mentioned in the offer documents and apply before the subscription window closes.
- Price Band
- ₹ 372 – 392
- Lot Size
- 38
- Issue Size
- ₹409 Cr
- Minimum Investment
- ₹14896 (38 Shares)
- Listing Date
- 02 April 2026
Current GMP
₹0 (0.00%)
*Info is indicative. Not an Investment Advice. Grey market trading is unregulated.
About Sai Parenteral's Limited
Incorporated in 2001, Sai Parenteral’s Ltd. is a diversified pharmaceutical formulations company with strong capabilities in research, development, and manufacturing.
The company operates through two primary business segments:
- Branded Generic Formulations
- Contract Development and Manufacturing Organisation (CDMO) services for both domestic and international markets
Sai Parenteral’s offers a broad product portfolio across multiple therapeutic areas, including cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, vitamins, minerals and supplements (VMS), analgesics, and dermatology. Its products are available in various dosage forms such as injectables, tablets, capsules, liquid orals, and ointments.
The company serves a diverse customer base comprising central and state government agencies, pharmaceutical companies, public and private hospitals, and super stockists across India.
In FY 2023, Sai Parenteral’s expanded into international markets following the acquisition of two internationally accredited manufacturing facilities in Hyderabad, Telangana. It now exports to regulated and semi-regulated markets, including Australia, New Zealand, Southeast Asia, the Middle East, and Africa.
Sai Parenteral’s operates five manufacturing facilities in India. Four of these are located in Hyderabad, Telangana, including:
- A GMP-compliant injectable unit
- A WHO-GMP certified injectable unit
- A TGA (Australia) and PIC/S accredited solid oral dosage facility
- A WHO-GMP certified cephalosporin unit
Additionally, its wholly owned subsidiary, Revat Laboratories, operates a GMP-certified manufacturing facility in Ongole, Andhra Pradesh.
As of August 31, 2025, the company employed 277 full-time staff members.
Sai Parenteral's IPO Promoters
- Anil Kumar Karusala
- Vijitha Gorrepati
- Karusala Aruna
Promoters Holding
Holding Pre Issue
61.23%
Holding Post Issue
0.00%
Sai Parenteral's IPO Objective
The Company Sai Parenteral's IPO proposes to utilise the Net Proceeds from the Issue towards the following objects.
- Capacity expansion and upgradation of manufacturing facilities
- Establishment of a new R&D centre
- Repayment / prepayment of certain outstanding borrowings
- Working capital requirements
- Investment in wholly owned subsidiary, Sai Parenterals Pte Limited (Singapore), in relation to the proposed acquisition of Noumed Pharmaceuticals Pty Limited (Australia)
- General corporate purposes
Address / Contact Info
Sai Parenteral's Ltd.
Plot No 39
5th floor, Lavanya Arcade Jayabheri Enclave
Gachibowli, K.V.Rangareddy, Seri Lingampally
Hyderabad, Telangana, 500032
Phone: +91 79979 91301
Email: cs@saiparenterals.com
Website: https://www.saiparenterals.com/
IPO Snapshot
Book Running Lead Managers
- Arihant Capital Markets Ltd
Disclaimer: This data is for informational purposes only and does not constitute investment advice. Figures shown are illustrative sample data.
Frequently Asked Questions
Everything you need to know before applying to an IPO.
Sai Parenteral's IPO is a Book-building IPO with a total issue size of ₹409 crore. The Sai Parenteral's IPO price band is ₹372 to 392 per share. The Sai Parenteral's IPO subscription opens on Tue, Mar 24, 2026, and closes on Fri, Mar 27, 2026. The Sai Parenteral's IPO will be listed on the BSE,NSE. Bigshare Services Pvt Ltd is the registrar for the Sai Parenteral's IPO.
The Sai Parenteral's IPO opens on Tue, Mar 24, 2026 and closes on Fri, Mar 27, 2026
Sai Parenteral's IPO Price Band is ₹372 to 392 per share.
Sai Parenteral's IPO lot size is 38 shares, Retail investors need a minimum investment of ₹14896 based on the upper price band
The minimum investment for Sai Parenteral's IPO is ₹14896, based on one lot of 38 shares at the upper price band of ₹392 per share.
Investors can apply for the Sai Parenteral's IPO through the ASBA (Application Supported by Blocked Amount) facility offered by their bank or through UPI using a SEBI-registered broker or trading app. Select the desired lot size, enter your bid within the price band, and submit the application before Fri, Mar 27, 2026. The application amount remains blocked until the Sai Parenteral's IPO allotment is finalized.
Sai Parenteral's IPO issue size is ₹409 crores.
Sai Parenteral's IPO allotment date is Wed, Jul 1, 2026.
The registrar for Sai Parenteral's IPO is Bigshare Services Pvt Ltd. Investors can go to Bigshare Services Pvt Ltd website to check Sai Parenteral's IPO allotment status, refund processing, and other IPO-related information.